Alpha Cognition Revenue Growth Rates (ACOG), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Alpha Cognition Inc.  (Nasdaq: ACOG)
 

ACOG's Revenue Growth by Quarter and Year

Alpha Cognition's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ACOG/growth
https://api.csimarket.com/api/v1/companies/ACOG/fundamentals
https://api.csimarket.com/api/v1/companies/ACOG/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ACOG Revenue (in millions $) FY 2027 FY 2026 FY 2025 FY 2024
4th Quarter December -
3rd Quarter September 7.78
2nd Quarter June 6.09
1st Quarter March 3.53
FY 17.40





ACOG Revenue third quarter 2027 Y/Y Growth Comment
Alpha Cognition Inc. achieved in the third quarter 2027, above Company average Revenue surge of 173.84% year on year, to $ 7.78 millions.

According to the results reported in the third quarter 2027, Alpha Cognition Inc. achieved the best Revenue growth in Biotechnology & Pharmaceuticals industry. While Alpha Cognition Inc.' s Revenue doubling of 173.84% ranks overall at the positon no. 0 in the third quarter 2027.


ACOG Revenue ( Y/Y Growth %) 2027
 FY 2026 FY 2025 FY 2024
4th Quarter December -
3rd Quarter September 173.84 %
2nd Quarter June 266.87 %
1st Quarter March 20.48 %
FY   -

Financial Statements
Alpha Cognition's third quarter 2027 Revenue $ 7.78 millions ACOG's Income Statement
Alpha Cognition's third quarter 2026 Revenue $ 2.84 millions Quarterly ACOG's Income Statement


ACOG Revenue (Quarter on Quarter Growth %)

 2027
 FY 2026 FY 2025 FY 2024
4th Quarter December -
3rd Quarter September 27.7 %
2nd Quarter June 72.52 %
1st Quarter March 26.52 %
FY (Year on Year)   -


Back to ACOG Growth rate Comparisons >> Back to ACOG Growth rate Comparisons >>


Revenue third quarter 2027 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #0

Revenue Y/Y Growth Statistics
High Average Low
267.56 % 153.99 % 20.66 %
 
Revenue third quarter 2027 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #0
Revenue Y/Y Growth Statistics
High Average Low
267.56 % 153.99 % 20.66 %
 

Revenue by Quarter for the Fiscal Years 2024, 2025, 2026, 2027

Alpha Cognition's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
72.42 % 25.48 % -43.4 %
(Jun 30 2026)  


ACOG's III. Quarter Q/Q Revenue Comment
Alpha Cognition Inc. achieved in the III. Quarter 2027 above company average sequential Revenue jump of 27.7%, to $ 7.78 millions, from $6.09 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry Alpha Cognition Inc. achieved highest sequential Revenue growth. While Alpha Cognition's Revenue growth quarter on quarter, overall rank is 0.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #0
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #0
Revenue Q/Q Growth Statistics
High Average Low
72.42 % 25.48 % -43.4 %
(Jun 30 2026)  


ACOG's III. Quarter Q/Q Revenue Comment
Alpha Cognition Inc. achieved in the III. Quarter 2027 above company average sequential Revenue jump of 27.7%, to $ 7.78 millions, from $6.09 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry Alpha Cognition Inc. achieved highest sequential Revenue growth. While Alpha Cognition's Revenue growth quarter on quarter, overall rank is 0.


Alpha Cognition's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 20.20
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking #
Seqeuential Revenue Change (TTM) 32.35 %
Seq. Revenue Growth (TTM) Overall Ranking #


Cumulative Revenue growth Comment
Alpha Cognition saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 173.84% year on year, to $ 20 millions if the fiscal year would have ended in Sep 30 2026.
Alpha Cognition's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Jun 30 2026. And, Alpha Cognition realized the fastest Revenue growth, in Biotechnology & Pharmaceuticals industry.
But from twelve months ended Jun 30 2026 rise was beneth at 32.35 % from $15.26 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%.

Alpha Cognition Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 0
Sector # 0
S&P 500 # 0
Cumulative Revenue growth Comment
Alpha Cognition saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 173.84% year on year, to $ 20 millions if the fiscal year would have ended in Sep 30 2026.
Alpha Cognition's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Jun 30 2026. And, Alpha Cognition realized the fastest Revenue growth, in Biotechnology & Pharmaceuticals industry.
But from twelve months ended Jun 30 2026 rise was beneth at 32.35 % from $15.26 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%.
The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 32.35 % increase from $15.26 millions in the period from Jun 30 2026 to Sep 30 2025.

Alpha Cognition Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ACOG's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Renovorx Inc 300.75%$ 300.752 millions
Aligos Therapeutics Inc 281.92%$ 281.916 millions
Clene Inc 273.33%$ 273.333 millions
Recursion Pharmaceuticals Inc 258.49%$ 258.493 millions
Nuvation Bio Inc 251.98%$ 251.977 millions
Seastar Medical Holding Corp246.99%$ 246.995 millions
Prime Medicine Inc 243.92%$ 243.918 millions
Urogen Pharma Ltd 227.16%$ 227.161 millions
Dianthus Therapeutics Inc 205.56%$ 205.556 millions
Bridgebio Pharma Inc 192.60%$ 192.602 millions
Bicycle Therapeutics Plc190.24%$ 190.242 millions
Gossamer Bio Inc 189.09%$ 189.085 millions
Alpha Cognition Inc.173.75%$ 173.751 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions
Volitionrx Limited157.28%$ 157.283 millions
Neuraxis Inc 149.92%$ 149.922 millions
Pluri Inc 140.19%$ 140.190 millions
Camp4 Therapeutics Corporation138.87%$ 138.868 millions
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions


About Alpha Cognition Revenue Growth Rates (ACOG), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Alpha Cognition Inc (CIK 1655923).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-26-118702
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Alpha Cognition Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.